Skip to main content
Journal cover image

A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)

Publication ,  Journal Article
Hope, WW; El-Ghazzawy, AG; Winterstein, BA; Blatnik, JA; Davis, SS; Greenberg, JA; Sanchez, NC; Pauli, EM; Tseng, DM; LeBlanc, KA; Roberts, KE ...
Published in: Annals of Medicine and Surgery
January 1, 2022

Background: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). Methods: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months. Results: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m2 received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm2, mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence). Conclusion: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm2 (43.3%) compared to defects <7.1 cm2 (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes.

Duke Scholars

Published In

Annals of Medicine and Surgery

DOI

ISSN

2049-0801

Publication Date

January 1, 2022

Volume

73

Related Subject Headings

  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hope, W. W., El-Ghazzawy, A. G., Winterstein, B. A., Blatnik, J. A., Davis, S. S., Greenberg, J. A., … Smith, E. F. (2022). A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial). Annals of Medicine and Surgery, 73. https://doi.org/10.1016/j.amsu.2021.103156
Hope, W. W., A. G. El-Ghazzawy, B. A. Winterstein, J. A. Blatnik, S. S. Davis, J. A. Greenberg, N. C. Sanchez, et al. “A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).” Annals of Medicine and Surgery 73 (January 1, 2022). https://doi.org/10.1016/j.amsu.2021.103156.
Hope WW, El-Ghazzawy AG, Winterstein BA, Blatnik JA, Davis SS, Greenberg JA, et al. A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial). Annals of Medicine and Surgery. 2022 Jan 1;73.
Hope, W. W., et al. “A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).” Annals of Medicine and Surgery, vol. 73, Jan. 2022. Scopus, doi:10.1016/j.amsu.2021.103156.
Hope WW, El-Ghazzawy AG, Winterstein BA, Blatnik JA, Davis SS, Greenberg JA, Sanchez NC, Pauli EM, Tseng DM, LeBlanc KA, Roberts KE, Bower CE, Parra-Davila E, Roth JS, Deeken CR, Smith EF. A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial). Annals of Medicine and Surgery. 2022 Jan 1;73.
Journal cover image

Published In

Annals of Medicine and Surgery

DOI

ISSN

2049-0801

Publication Date

January 1, 2022

Volume

73

Related Subject Headings

  • 3202 Clinical sciences